Related Experiment Video
Updated: Jul 6, 2025
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence
Ziqiang Fan1, Yingdong Tong1, Ziyue Yang1
1Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu, Sichuan 611130, PR China.
Abstract:
Aging is a gradual process of natural change that occurs after reaching sexual maturity. It is also a known risk factor for many chronic diseases. Recent research has shown that senolytics can extend the lifespans and health spans of model organisms, and they have also been demonstrated effective in treating age-related diseases. In this study, we conducted a high-throughput screening of 156 drugs that targeted the PI3K/AKT/mTOR pathway to identify potential senolytic medications. Among these drugs, PF-04691502 was selected for further investigation to understand its molecular mechanism of action. Our findings indicate that PF-04691502, a dual inhibitor of PI3K/AKT and mTOR, specifically eliminates senescent cells. It reduces the expression levels of key markers of cellular senescence, such as SA-β-Gal, senescence-associated secretory phenotypes (SASPs) and p16INK4a. Additionally, PF-04691502 inhibits the phosphorylation of S6K and AKT, leading to the apoptosis of senescent cells. These results suggest that PF-04691502 holds promise as a new senolytic drug. This paper provides important insights into the potential application of PF-04691502 in the study of cell senescence.
Insights
Researchers screened 156 drugs targeting the PI3K/AKT/mTOR pathway for senolytic potential. PF-04691502 effectively eliminated senescent cells by inhibiting key signaling pathways, showing promise as a novel senolytic drug.
Area of Science:
- Gerontology and Cellular Biology
- Pharmacology and Drug Discovery
Background:
- Aging is a natural process linked to chronic diseases.
- Senolytics show promise in extending lifespan and treating age-related conditions.
- Cellular senescence plays a critical role in aging and disease pathogenesis.
Purpose of the Study:
- To identify novel senolytic drugs by screening compounds targeting the PI3K/AKT/mTOR pathway.
- To investigate the molecular mechanism of action of PF-04691502 as a senolytic agent.
- To evaluate the efficacy of PF-04691502 in eliminating senescent cells.
Main Methods:
- High-throughput screening of 156 drugs targeting the PI3K/AKT/mTOR pathway.
- In vitro investigation of PF-04691502's effect on senescent cells.
- Analysis of senescence markers (SA-β-Gal, SASPs, p16INK4a) and signaling pathway inhibition (p-S6K, p-AKT).
Main Results:
- PF-04691502, a dual PI3K/AKT and mTOR inhibitor, was identified as a potential senolytic drug.
- PF-04691502 significantly reduced senescence markers, including SA-β-Gal, SASPs, and p16INK4a.
- The drug inhibited AKT and S6K phosphorylation, inducing apoptosis in senescent cells.
Conclusions:
- PF-04691502 demonstrates specific senolytic activity by targeting the PI3K/AKT/mTOR pathway.
- PF-04691502 effectively eliminates senescent cells and reduces key senescence markers.
- This study highlights PF-04691502 as a promising candidate for senolytic therapy and further research into cell senescence.
